CN113454459A - 诊断方法 - Google Patents

诊断方法 Download PDF

Info

Publication number
CN113454459A
CN113454459A CN202080015187.6A CN202080015187A CN113454459A CN 113454459 A CN113454459 A CN 113454459A CN 202080015187 A CN202080015187 A CN 202080015187A CN 113454459 A CN113454459 A CN 113454459A
Authority
CN
China
Prior art keywords
subject
adiponectin
antibody
pancreatitis
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080015187.6A
Other languages
English (en)
Chinese (zh)
Inventor
E·科斯特洛
W·格林哈尔弗
L·奥德菲尔德
C·哈洛伦
P·加奈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liverpool
Original Assignee
University of Liverpool
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1902193.0A external-priority patent/GB201902193D0/en
Priority claimed from GBGB1903424.8A external-priority patent/GB201903424D0/en
Application filed by University of Liverpool filed Critical University of Liverpool
Publication of CN113454459A publication Critical patent/CN113454459A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/067—Pancreatitis or colitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN202080015187.6A 2019-02-18 2020-02-17 诊断方法 Pending CN113454459A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1902193.0 2019-02-18
GBGB1902193.0A GB201902193D0 (en) 2019-02-18 2019-02-18 Method of diagnosis
GB1903424.8 2019-03-13
GBGB1903424.8A GB201903424D0 (en) 2019-03-13 2019-03-13 Method of diagnosis
PCT/EP2020/054046 WO2020169511A1 (en) 2019-02-18 2020-02-17 Method of diagnosis

Publications (1)

Publication Number Publication Date
CN113454459A true CN113454459A (zh) 2021-09-28

Family

ID=69591656

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080015187.6A Pending CN113454459A (zh) 2019-02-18 2020-02-17 诊断方法

Country Status (7)

Country Link
US (1) US20220091140A1 (OSRAM)
EP (1) EP3903105A1 (OSRAM)
JP (1) JP7660077B2 (OSRAM)
CN (1) CN113454459A (OSRAM)
AU (1) AU2020223826A1 (OSRAM)
CA (1) CA3127569A1 (OSRAM)
WO (1) WO2020169511A1 (OSRAM)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108138238A (zh) * 2015-07-28 2018-06-08 约翰霍普金斯大学 用于检测胰腺癌的组合物和方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2459489C (en) * 2001-08-17 2010-02-02 Rebio Gen, Inc. Method for diagnosing or monitoring carbohydrate metabolism disorders
AU2004205898B2 (en) * 2003-01-17 2009-11-19 The Research Foundation Of State University Of New York Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
US20060105419A1 (en) * 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
US8632983B2 (en) * 2005-04-15 2014-01-21 Van Andel Research Institute Biomarkers for pancreatic cancer and diagnostic methods
CA2645125A1 (en) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Methods for diagnosing pancreatic cancer using reg4 protein
WO2011157756A1 (en) * 2010-06-15 2011-12-22 Roche Diagnostics Gmbh Prediction and recognition of acute kidney injury after surgery
JP2014510516A (ja) * 2011-02-15 2014-05-01 ノヴォ ノルディスク アー／エス 長時間作用性ｉｌ−１受容体アンタゴニスト
US9402919B2 (en) * 2011-03-04 2016-08-02 Intrexon Corporation Vectors conditionally expressing protein
GB201103726D0 (en) * 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
US20160231334A1 (en) * 2013-10-28 2016-08-11 The Forsyth Institute Compositions and Methods for Evaluating Metabolic Syndrome and Related Diseases
WO2015112429A1 (en) 2014-01-23 2015-07-30 Newomics Inc Methods and systems for diagnosing diseases
WO2015157557A1 (en) 2014-04-09 2015-10-15 Myriad Rbm, Inc. Methods of diagnosing pancreatic cancer and methods related thereto
US10303846B2 (en) * 2014-08-14 2019-05-28 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
WO2016065202A1 (en) * 2014-10-22 2016-04-28 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Blood biomarkers for appendicitis and diagnostics methods using biomarkers
GB201522839D0 (en) 2015-12-23 2016-02-03 Randox Lab Ltd And Randox Teoranta Method
GB201608192D0 (en) * 2016-05-10 2016-06-22 Immunovia Ab Method, array and use thereof
US12416636B2 (en) * 2018-05-31 2025-09-16 University Of Florida Research Foundation, Inc. Personalized treatment of pancreatic cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108138238A (zh) * 2015-07-28 2018-06-08 约翰霍普金斯大学 用于检测胰腺癌的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EWA KONTNY等: "Comparison of rheumatoid articular adipose and synovial tissue reactivity to proinfl ammatory stimuli: contribution to adipocytokine network", ANN RHEUM DIS, vol. 71, pages 262 - 267 *

Also Published As

Publication number Publication date
JP7660077B2 (ja) 2025-04-10
AU2020223826A1 (en) 2021-08-05
JP2022529073A (ja) 2022-06-16
EP3903105A1 (en) 2021-11-03
CA3127569A1 (en) 2020-08-27
WO2020169511A1 (en) 2020-08-27
US20220091140A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
Al-Sawaf et al. Body composition and lung cancer-associated cachexia in TRACERx
US20250216393A1 (en) Plasma autoantibody biomarkers for diagnosis of lung cancer
Rho et al. Protein and glycomic plasma markers for early detection of adenoma and colon cancer
Thorsvik et al. Fecal neutrophil gelatinase‐associated lipocalin as a biomarker for inflammatory bowel disease
Jenkinson et al. Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus
JP6774925B2 (ja) 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療のための方法並びにそのキット
Bourgonje et al. Increased fecal calprotectin levels in Crohn’s disease correlate with elevated serum Th1-and Th17-associated cytokines
Ang et al. Targeted in-gel MRM: a hypothesis driven approach for colorectal cancer biomarker discovery in human feces
CN106461677B (zh) 肺高血压病的检查方法
JP2020091295A (ja) 膵臓がんを検出するための方法および組成物
JP2020510816A (ja) 肺癌の検出および処置のための方法
Bodelon et al. Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer
Lipshitz et al. Emerging markers of cancer cachexia and their relationship to sarcopenia
JP2019527361A (ja) 大腸癌の併用検査
CN113785199B (zh) 用于诊断结肠直肠癌和/或其癌前阶段的蛋白质特征
Do et al. Quantitative proteomic analysis of pancreatic cyst fluid proteins associated with malignancy in intraductal papillary mucinous neoplasms
Nantais-Smith et al. Noninvasive biomarkers of necrotizing enterocolitis
JP5704684B2 (ja) ＩｇＧ４関連疾患診断用マーカー及びその利用
Kovacevic et al. Urine proteomic analysis in cystinuric children with renal stones
Chen et al. Clinical study of serum IGFBP7 in predicting lymphatic metastasis in patients with lung adenocarcinoma
JP7660077B2 (ja) 診断方法
CN109696547B (zh) 一种判断结直肠癌预后的标志物及其应用
WO2016111507A1 (ko) 신규 간암 환자의 소라페닙 저항성 예측 마커
CN114286942B (zh) 检测癌症的方法
Choi et al. KRAS mutation analysis by droplet digital PCR of duodenal juice from patients with MODY8 and other pancreatic diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210928

WD01 Invention patent application deemed withdrawn after publication